Michael Burkes Brophy Sells 1,238 Shares of Natera, Inc. (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy sold 1,238 shares of the business’s stock in a transaction dated Monday, April 29th. The shares were sold at an average price of $93.14, for a total value of $115,307.32. Following the completion of the sale, the chief financial officer now directly owns 69,408 shares of the company’s stock, valued at $6,464,661.12. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Michael Burkes Brophy also recently made the following trade(s):

• On Thursday, April 25th, Michael Burkes Brophy sold 705 shares of Natera stock. The shares were sold at an average price of $89.55, for a total value of $63,132.75.
• On Tuesday, April 23rd, Michael Burkes Brophy sold 1,523 shares of Natera stock. The stock was sold at an average price of $91.38, for a total value of $139,171.74.
• On Tuesday, April 2nd, Michael Burkes Brophy sold 1,378 shares of Natera stock. The stock was sold at an average price of $92.62, for a total value of $127,630.36.
• On Thursday, March 28th, Michael Burkes Brophy sold 914 shares of Natera stock. The stock was sold at an average price of $90.42, for a total value of $82,643.88.
• On Tuesday, March 5th, Michael Burkes Brophy sold 2,826 shares of Natera stock. The stock was sold at an average price of $88.36, for a total value of $249,705.36.
• On Tuesday, February 6th, Michael Burkes Brophy sold 34,029 shares of Natera stock. The stock was sold at an average price of $70.03, for a total value of $2,383,050.87.
• On Thursday, February 1st, Michael Burkes Brophy sold 22,281 shares of Natera stock. The stock was sold at an average price of $67.73, for a total value of $1,509,092.13.

Natera Price Performance

Natera stock opened at $93.72 on Friday. Natera, Inc. has a 12 month low of $36.90 and a 12 month high of $98.82. The company has a current ratio of 4.10, a quick ratio of 3.96 and a debt-to-equity ratio of 0.37. The business’s 50 day simple moving average is $90.02 and its 200 day simple moving average is $68.91. The company has a market cap of $11.46 billion, a price-to-earnings ratio of -24.73 and a beta of 1.38.

Natera (NASDAQ:NTRA) last posted its quarterly earnings data on Wednesday, February 28th. The medical research company reported ($0.64) EPS for the quarter, beating the consensus estimate of ($0.73) by $0.09. Natera had a negative return on equity of 62.19% and a negative net margin of 40.16%. The business had revenue of $311.11 million for the quarter, compared to the consensus estimate of $300.38 million. Sell-side analysts forecast that Natera, Inc. will post -2.35 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the company. The Goldman Sachs Group boosted their price objective on Natera from $90.00 to $100.00 and gave the stock a “buy” rating in a report on Monday, April 15th. Piper Sandler upped their target price on Natera from $70.00 to $110.00 and gave the company an “overweight” rating in a report on Wednesday, March 6th. Stephens reaffirmed an “overweight” rating and issued a $78.00 target price on shares of Natera in a report on Tuesday, January 30th. Raymond James lowered Natera from a “strong-buy” rating to an “outperform” rating and upped their target price for the company from $68.00 to $85.00 in a report on Tuesday, February 20th. Finally, StockNews.com raised Natera from a “sell” rating to a “hold” rating in a report on Wednesday. One equities research analyst has rated the stock with a hold rating and fourteen have given a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $86.40.

Institutional Investors Weigh In On Natera

Institutional investors have recently made changes to their positions in the stock. Allspring Global Investments Holdings LLC lifted its position in shares of Natera by 28.6% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 720,160 shares of the medical research company’s stock worth $45,111,000 after acquiring an additional 159,993 shares in the last quarter. Cerity Partners LLC lifted its position in shares of Natera by 1,043.3% during the fourth quarter. Cerity Partners LLC now owns 90,423 shares of the medical research company’s stock worth $5,664,000 after acquiring an additional 82,514 shares in the last quarter. WCM Investment Management LLC lifted its position in shares of Natera by 101.2% during the fourth quarter. WCM Investment Management LLC now owns 145,996 shares of the medical research company’s stock worth $9,058,000 after acquiring an additional 73,419 shares in the last quarter. abrdn plc purchased a new stake in shares of Natera during the fourth quarter worth $3,214,000. Finally, Aigen Investment Management LP purchased a new stake in shares of Natera during the third quarter worth $223,000. Hedge funds and other institutional investors own 99.90% of the company’s stock.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.